Eicosanoids, β-cell function, and diabetes

Pengcheng Luo, Mong-Heng Wang

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

Arachidonic acid (AA) is metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in diverse diseases, including type 1 and type 2 diabetes. During the last 30 years, evidence has been accumulated that suggests important functions for eicosanoids in the control of pancreatic β-cell function and destruction. AA metabolites of the COX pathway, especially prostaglandin E 2 (PGE 2), appear to be significant factors to β-cell dysfunction and destruction, participating in the pathogenesis of diabetes and its complications. Several elegant studies have contributed to the sorting out of the importance of 12-LOX eicosanoids in cytokine-mediated inflammation in pancreatic β cells. The role of CYP eicosanoids in diabetes is yet to be explored. A recent publication has demonstrated that stabilizing the levels of epoxyeicosatrienoic acids (EETs), CYP eicosanoids, by inhibiting or deleting soluble epoxide hydrolase (sEH) improves β-cell function and reduces β-cell apoptosis in diabetes. In this review we summarize recent findings implicating these eicosanoid pathways in diabetes and its complications. We also discuss the development of animal models with targeted gene deletion and specific enzymatic inhibitors in each pathway to identify potential targets for the treatment of diabetes and its complications.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalProstaglandins and Other Lipid Mediators
Volume95
Issue number1-4
DOIs
StatePublished - Aug 1 2011

Fingerprint

Eicosanoids
Medical problems
Cytochrome P-450 Enzyme System
Diabetes Complications
Prostaglandin-Endoperoxide Synthases
Arachidonic Acid
Arachidonate 12-Lipoxygenase
Epoxide Hydrolases
Lipoxygenase
Gene Deletion
Metabolites
Prostaglandins E
Type 1 Diabetes Mellitus
Sorting
Type 2 Diabetes Mellitus
Animals
Animal Models
Genes
Apoptosis
Cytokines

Keywords

  • 12-HETE
  • Cyclooxygenase
  • Cytochrome P450
  • EETs
  • Lipoxygenase
  • PGE2
  • sEH
  • β-Cell destruction
  • β-Cell function

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology

Cite this

Eicosanoids, β-cell function, and diabetes. / Luo, Pengcheng; Wang, Mong-Heng.

In: Prostaglandins and Other Lipid Mediators, Vol. 95, No. 1-4, 01.08.2011, p. 1-10.

Research output: Contribution to journalReview article

@article{d63a3c740b8f4c14a9a7320077de2cbe,
title = "Eicosanoids, β-cell function, and diabetes",
abstract = "Arachidonic acid (AA) is metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in diverse diseases, including type 1 and type 2 diabetes. During the last 30 years, evidence has been accumulated that suggests important functions for eicosanoids in the control of pancreatic β-cell function and destruction. AA metabolites of the COX pathway, especially prostaglandin E 2 (PGE 2), appear to be significant factors to β-cell dysfunction and destruction, participating in the pathogenesis of diabetes and its complications. Several elegant studies have contributed to the sorting out of the importance of 12-LOX eicosanoids in cytokine-mediated inflammation in pancreatic β cells. The role of CYP eicosanoids in diabetes is yet to be explored. A recent publication has demonstrated that stabilizing the levels of epoxyeicosatrienoic acids (EETs), CYP eicosanoids, by inhibiting or deleting soluble epoxide hydrolase (sEH) improves β-cell function and reduces β-cell apoptosis in diabetes. In this review we summarize recent findings implicating these eicosanoid pathways in diabetes and its complications. We also discuss the development of animal models with targeted gene deletion and specific enzymatic inhibitors in each pathway to identify potential targets for the treatment of diabetes and its complications.",
keywords = "12-HETE, Cyclooxygenase, Cytochrome P450, EETs, Lipoxygenase, PGE2, sEH, β-Cell destruction, β-Cell function",
author = "Pengcheng Luo and Mong-Heng Wang",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.prostaglandins.2011.06.001",
language = "English (US)",
volume = "95",
pages = "1--10",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier BV",
number = "1-4",

}

TY - JOUR

T1 - Eicosanoids, β-cell function, and diabetes

AU - Luo, Pengcheng

AU - Wang, Mong-Heng

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Arachidonic acid (AA) is metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in diverse diseases, including type 1 and type 2 diabetes. During the last 30 years, evidence has been accumulated that suggests important functions for eicosanoids in the control of pancreatic β-cell function and destruction. AA metabolites of the COX pathway, especially prostaglandin E 2 (PGE 2), appear to be significant factors to β-cell dysfunction and destruction, participating in the pathogenesis of diabetes and its complications. Several elegant studies have contributed to the sorting out of the importance of 12-LOX eicosanoids in cytokine-mediated inflammation in pancreatic β cells. The role of CYP eicosanoids in diabetes is yet to be explored. A recent publication has demonstrated that stabilizing the levels of epoxyeicosatrienoic acids (EETs), CYP eicosanoids, by inhibiting or deleting soluble epoxide hydrolase (sEH) improves β-cell function and reduces β-cell apoptosis in diabetes. In this review we summarize recent findings implicating these eicosanoid pathways in diabetes and its complications. We also discuss the development of animal models with targeted gene deletion and specific enzymatic inhibitors in each pathway to identify potential targets for the treatment of diabetes and its complications.

AB - Arachidonic acid (AA) is metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in diverse diseases, including type 1 and type 2 diabetes. During the last 30 years, evidence has been accumulated that suggests important functions for eicosanoids in the control of pancreatic β-cell function and destruction. AA metabolites of the COX pathway, especially prostaglandin E 2 (PGE 2), appear to be significant factors to β-cell dysfunction and destruction, participating in the pathogenesis of diabetes and its complications. Several elegant studies have contributed to the sorting out of the importance of 12-LOX eicosanoids in cytokine-mediated inflammation in pancreatic β cells. The role of CYP eicosanoids in diabetes is yet to be explored. A recent publication has demonstrated that stabilizing the levels of epoxyeicosatrienoic acids (EETs), CYP eicosanoids, by inhibiting or deleting soluble epoxide hydrolase (sEH) improves β-cell function and reduces β-cell apoptosis in diabetes. In this review we summarize recent findings implicating these eicosanoid pathways in diabetes and its complications. We also discuss the development of animal models with targeted gene deletion and specific enzymatic inhibitors in each pathway to identify potential targets for the treatment of diabetes and its complications.

KW - 12-HETE

KW - Cyclooxygenase

KW - Cytochrome P450

KW - EETs

KW - Lipoxygenase

KW - PGE2

KW - sEH

KW - β-Cell destruction

KW - β-Cell function

UR - http://www.scopus.com/inward/record.url?scp=79960837542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960837542&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2011.06.001

DO - 10.1016/j.prostaglandins.2011.06.001

M3 - Review article

C2 - 21757024

AN - SCOPUS:79960837542

VL - 95

SP - 1

EP - 10

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

IS - 1-4

ER -